key: cord-0775172-osg9dre5 authors: Kadali, Renuka Ananth Kalyan; Janagama, Ravali; Yedlapati, Siva H.; Kanike, Neelakanta; Gajula, Viswanath; Madathala, Rajasekhar R.; Poddar, Swati; Sukka, Neelakanta; Jogu, Hanumantha R.; Racherla, Shailaja title: Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study date: 2021-10-28 journal: Am J Infect Control DOI: 10.1016/j.ajic.2021.10.017 sha: 44838d7f8250a4596a36dffb0a2c041b33fb80d3 doc_id: 775172 cord_uid: osg9dre5 BACKGROUND: There are concerns regarding immunogenicity with COVID-19 mRNA vaccines among persons with prior history of COVID-19 (PHC). This study was to analyze the short-term side effects of mRNA vaccines among healthcare workers (HCWs) with and without PHC. METHODS: A cross-sectional study was performed using an independent online survey questionnaire that gathered responses from HCWs. RESULTS: Among 1475 HCWs, 1268 (85.97%) completed the survey, 102/1268 (44/447 in Moderna group and 58/821 in Pfizer-BioNTech group) reported PHC during pre-vaccination period. Symptoms of flushing/p= 0.05, brain fogging/p= 0.005, vertigo/p= 0.041, numbness/p= 0.023, diarrhea/p= 0.047, hives/p= 0.028, itching/p= 0.028, swelling of lips/mouth/p= 0.001, shortness of breath/p= 0.022, and anxiety/p= 0.048 have greater occurrence among Pfizer-BioNtech group with PHC when compared to Pfizer-BioNtech group with no PHC. Symptoms of chills/p= 0.027, flushing/p= 0.045, tremor/p= 0.05, muscle spasm/p= 0.039, vomiting/p= 0.031, diarrhea/p= 0.015, and cough/p= 0.011 have higher occurrence among Moderna group with PHC when compared to Moderna group with no PHC. CONCLUSIONS: Few short-term side effects among mRNA vaccine recipients with PHC may have necessitated transient time-off from work. The PHC can be considered as a predictor for severity of side effects. While the vaccination program continues in the United States, a future COVID legislation that mandates vaccination among employees along with paid time off provision may help with higher compliance and acceptance. October 2020 [1] . COVID-19 related deaths as of September 15th, 2021, in the US were about 658,754 [2] . The US is currently experiencing a full swing of third surge in infections posing a significant burden to healthcare system and severe economic consequences [2, 3] . Several parts of US are already experiencing a third surge in COVID-19 infections posing a significant burden to healthcare system with lockdowns and severe economic consequences [3] . To alter these trends and flatten the curve, Food and Drug Administration (FDA) in the US has authorized two mRNA vaccines (the Pfizer-BioNTech manufactured BNT162b2 vaccine, and the Moderna manufactured mRNA-1273 vaccine [4, 5] . While the active ingredient of both mRNA vaccines encodethe viral spike (S) glycoprotein of SARS-CoV-2], each dose of the Moderna vaccine contains more vaccine (100 micrograms) than each dose of the Pfizer-BioNtech vaccine (30 micrograms) [6] . In December 2020, the Advisory Committee on Immunization Practices (ACIP) issued recommendations for the use of a two-dose regimen of BNT162b2 COVID-19 mRNA vaccine (which was shown to have 95% efficacy in protection against COVID-19) in persons aged 16 years or older [5] , and two-dose regimen of mRNA-1273 vaccine (which was shown to have 94.1% efficacy in preventing COVID-19, including severe disease) [4] . Data from the recent studies with detailed review of systems among mRNA COVID-19 vaccine recipients suggests that they would experience wide range of non-life threatening local and systemic post-vaccination symptoms but still has greater acceptance to these vaccines [4, 5, 7, 8, 9] . Clinical trials have generally excluded patients with history of COVID-19, and it is unclear if this cohort will experience more post-vaccination side effects from mRNA vaccine [4, 5] . However, Centers for Disease Control and Prevention (CDC) stated that the side effects in early post-vaccination period can be severe and higher in recipients with prior infection, but the details of symptomatology were not studied or revealed [6] . The objective of the present study was to analyze the safety and more detailed side effect profile of the mRNA vaccine using a selfreported online survey questionnaire among recipients with prior history of COVID-19. Therefore, we chose a random population of health care workers (HCW) in the United States and investigated the side effects of these vaccines using responses from the survey questionnaire [consisting of a more detailed review of organ systems in comparison to what the CDC is collecting through the Vaccine Adverse Event Reporting System (VAERS)] [10] . After obtaining institutional review board (IRB) approval for this research, we conducted a cross-sectional study by circulating an independent online survey questionnaire through an internet-based survey platform called 'Survey Monkey', which gathered anonymous responses from HCWs from verified healthcare communities representing different unspecified regions of the country during the early phase of COVID-19 vaccination. No personal identifications were obtained. Survey Monkey web link was distributed to (1) coordinators of healthcare institutions and (2) verified communities of HCWs via social media. Informed consent was obtained at the beginning of the survey. Participants who voluntarily agreed and consented to proceed and who chose to receive one of the two mRNA-based COVID-19 vaccines were automatically allowed to move forward to answer subsequent questions about the side effects and other variables. Those who chose 'None of them' were diverted to a disqualified page. The study obtained feedback in anonymous mode regarding the side effect and benefit profile (feelings of joy/relief/gratitude) during the post-vaccination period. This study included the healthcare providers and workers in healthcare settings (Phase 1a vaccine recipients who may be exposed to suspect or confirmed COVID-19 pa-tients or infective materials) that have received one or two doses of the mRNA-based COVID-19 vaccine. Figure 1 ). The study was conducted on HCWs and these respondents were stratified by the type of vaccine administered, the side effect reported and as well as having a PHC (yes/no). The percentage of response was calculated for each of the respective categories. The significance of association between the PHC and the related side effect for each type of vaccine was determined using Fisher's exact t test with an alpha threshold level of 0.05 was chosen for this study to identify the differences. In this cross-sectional survey study among HCWs, the post-vaccination side effects in those who Thus far, the available data on mRNA-based COVID-19 vaccine short-term side effects have been reported by manufacturer-funded clinical trials and recent cross-sectional studies [4, 5, 7, 8, 9] . There was also greater acceptance for the second dose in spite of side effects [7, 8, 9] . A greater percentage of participants who received the Moderna vaccine, compared with the Pfizer-BioNTech vaccine, reported reactogenicity; this pattern was more pronounced after the second dose [11] . Our findings were consistent with these reports, however, we reported more detailed review of organ systems. The frequency of reported reactions was slightly higher in our cohort compared with those observed in clinical trials [4, 5, 11] . The uniqueness of our survey was to report and compare the side effects experienced in those with and without prior history to COVID-19 infection which was largely excluded in these clinical trials [4, 5] . Our study demonstrated a significant association between a prior COVID-19 infection and incidence of self-reported side effects after a vaccination for COVID-19. Recent survey study reported that a prior history of COVID-19 was associated with the risk of experiencing a severe side effect requiring hospital care [1.56 (1.14-2.12)] however, none of our study participants with a prior history of COVID-19 reported to require hospitalization [12] . This finding can be explained by recent studies demonstrating that seropositive individuals developed rapid immune responses with higher antibody titers after the first vaccination dose compared with those without a previous COVID-19 infection [13, 14] . Although the short-term side effects reported in Table-1 were attributed directly to the vaccine, some of the pre-existing chronic medical problems such as (prior history of atopic or food or drug allergies, asthma, and or other illness reported in Table- 2) may have contributed to some of these side effects, or they could be an unfortunate coincidence from new underlying medical problems that are not related to the vaccine. Chronic medical problems such as heart attacks, lung problems, blood disorders, cancer, stroke, and several other illnesses (reported in Table- 2), have occurred before the pandemic and will continue to occur. The excipients (the inactive ingredients which are used in the mRNA vaccine to stimulate a stronger immune response, prevent bacterial contamination, and stabilize the potency of the vaccine during transportation and storage) are the major contributors to specific IgE-mediated and immediate reactions associated with vaccines [15] . Another key finding in our study is that a The main strengths of our study included a large study population which reflected real-life compared with the populations studied in the clinical trials, the availability of much detailed organ system-based symptomatology experienced, adequate details about the participants and the safety profiles of the vaccines. There are several limitations to our study. The potential recall bias through the study population is HCWs who would more than likely remember the symptoms they experienced. The sample of the study is a convenient sample and so the conclusions were attributed to the given sample but did not infer to the total population. Most of the symptoms reported are within the early post-vaccination phase of the vaccine, so the latent effects could not be identified. Although, we did not gather information on history of allergies, only about 18% of vaccine recipients experienced mild-moderate allergic reactions. Of note, the investigators believed that the sensitivity of symptoms perceived by healthcare workers (HCWs) might be more accurate and reliable with their higher level of education and their day-to-day experience in the healthcare field when compared to general population. Our questionnaire with the extended number of questions has covered a wide range of organ systems (with a long list of symptomatology) than any other study or the original vaccine trial. Also, we tried to avoid the response fatigue from survey respondents from general population but the results discussed above can be extended to general population. Our independent survey among HCW focused on a detailed review of organ systems and was not limited to those mentioned in the VAERS system managed by CDC [10] . The PHC can be considered as a predictor for severity of short-term side effects from messenger RNA vaccines. Setting expectations with patients may alleviate some of the potential anxiety elicited by postvaccination side effects. While the vaccination program continues in the United States, a future COVID related legislation (facilitating for mandatory vaccination among employees along with providing paid time off for vaccine-related side effects) may help promote employees with higher compliance and acceptance with the vaccination especially in those to recover from unpleasant non-threatening vaccine-related side effects. COVID-19 as the Leading Cause of Death in the United States NVSS -Provisional Death Counts for COVID-19 -Executive Summary Are Overwhelmed Health Systems an Inevitable Consequence of Covid-19? Experiences from China Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States Side Effects of BNT162b2 mRNA COVID-19 Vaccine: A Randomized, Cross-Sectional Study with Detailed Self-Reported Symptoms from Healthcare Workers Non-Life-Threatening Adverse Effects with COVID-19 mRNA-1273 Vaccine: A Randomized, Cross-Sectional Study on Healthcare Workers with Detailed Self-Reported Symptoms Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed self-reported symptoms First Month of COVID-19 Vaccine Safety Monitoring -United States Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines Vaccines: A Vaccine Recipient Survey Vaccines: A Vaccine Recipient Survey Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Binding and Neutralization Antibody Titers after a Single Vaccine Dose in Health Care Workers Previously Infected with SARS-CoV-2 mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach